Insight Molecular Diagnostics (IMDX) Short-term Investments (2015 - 2026)

Insight Molecular Diagnostics has disclosed Short-term Investments across 11 years of filings, most recently posting $729000.0 for Q1 2026.

• Short-term Investments for Q1 2026 came in at $729000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $729000.0 (changed N/A YoY), and the FY2025 annual result was $729000.0, changed N/A from the prior year.
• Short-term Investments came in at $729000.0 for Q1 2026 at Insight Molecular Diagnostics, roughly flat from $729000.0 in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $729000.0 in Q3 2025 to a low of $400000.0 in Q3 2022.
• The 4-year median for Short-term Investments is $589500.0 (2022), against an average of $577000.0.
• Across the five-year window, Short-term Investments plunged 55.56% in 2022 and increased 10.25% in 2023, its largest moves.
• Insight Molecular Diagnostics' Short-term Investments stood at $433000.0 in 2022, then gained by 1.85% to $441000.0 in 2023, then soared by 65.31% to $729000.0 in 2025, then changed by 0.0% to $729000.0 in 2026.
• The last three Short-term Investments figures came in at $729000.0 (Q1 2026), $729000.0 (Q4 2025), and $729000.0 (Q3 2025), per Business Quant data.